On this page, Cancer.Net offers news for patients about the cancer care and treatment advances announced during the American Society of Clinical Oncology's (ASCO) Annual Meeting each year.
The ASCO Annual Meeting is the premier educational and scientific event where physicians, researchers, and other health-care professionals gather to discuss the latest in cancer care. News announced during each meeting includes the latest findings from cancer clinical trials, including new drug studies, that could change current standards of care. Cancer.Net's information helps people with cancer, and their families and friends, put into context such results and other news that is announced during the meeting.
Below is a range of patient-friendly materials on highlighted research and news from the 2009 Annual Meeting (held May 29-June 2) including videos, audio podcasts, and a searchable archive of abstract summaries. The next ASCO Annual Meeting will be held in Chicago, Illinois, on June 4-8, 2010.
Olivia Newton-John Launches Kaleidoscope Initiative at the ASCO Annual Meeting
News Videos From the 2009 ASCO Annual Meeting
Advances in the Quality of Cancer Care
Advances in the Clinical Challenges of Oncology
Advances in Women's Cancers
Advances in Personalized Cancer Care
Advances in Lung Cancer
Advances in Gastrointestinal Cancers
Podcasts featuring news from the 2009 ASCO Annual Meeting can be found on the Cancer.Net Podcasts page.
View The Group Room's Live Webcast From the 2009 ASCO Annual Meeting - May 31st, 4-6 PM ET.
Using the drop-down menu below, learn more about news from ASCO's Annual Meetings since 2002. You can select a specific year and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
In addition to the highlighted studies below, thousands of scientific abstracts are released each year at the ASCO Annual Meeting. To search the entire collection of meeting abstracts, visit ASCO’s website.
Researchers found that a vaccine called BiovaxID delayed the return of a type of B-cell lymphoma, called follicular lymphoma, by about 14 months for patients whose lymphoma was in remission (the temporary or permanent absence of disease) after treatment with prednisone (multiple brand names), doxorubicin (Adriamycin), cyclophosphamide (Cytoxan, Clafen, Neosar), and etoposide (VePesid, Toposar) – a combination called PACE.
In two separate studies, researchers found that two new drugs belonging to a group of drugs called PARP inhibitors may help treat some types of breast cancer. PARP inhibitors stop cancer cells from repairing damage from chemotherapy, which may make cancer cells more sensitive to chemotherapy.
A new report from the Childhood Cancer Survivor Study (CCSS) showed that childhood cancer survivors were almost five times more likely to have post-traumatic stress disorder (PTSD) than their siblings who did not have cancer as children.
A new study showed that patients who received moisturizers, sunscreen, topical steroids, and antibiotics before treatment with panitumumab (Vectibix) were less likely to have a rash from treatment than patients who did not receive the skin treatments until the rash developed.
Recent research compared treatments for locally advanced cervical cancer and the effect of different lymph node (tiny, bean-shaped organs that help fight infection) removal techniques for early-stage cervical cancer. Another study looked at when to start treatment for ovarian cancer recurrence. In addition, a national survey provided information about discussing fertility preservation.
Researchers found that patients with non-small cell lung cancer (NSCLC) whose tumors had no or low levels of a protein called MSH2, benefitted more from chemotherapy after surgery than patients with high levels of MSH2.
New studies on breast cancer recurrence look at radiation therapy techniques, drugs that may interfere with tamoxifen (Nolvadex), and the removal of lymph nodes (tiny, bean-shaped organs that help fight infection).
Patients screened for lung cancer recurrence (return of cancer after treatment) with low-dose computed tomography (LDCT) showed more false-positive results (meaning that the test shows that cancer is present when follow-up testing finds no cancer) than a chest x-ray, according to a new study.